Lineage Cell Therapeutics Inc (AMEX:LCTX) shares, rose in value, with the stock price up by 5.88% to the previous day’s close as strong demand from buyers drove the stock to $1.44.
Actively observing the price movement in the last trading, the stock closed the session at $1.36. The value of beta (5-year monthly) was 1.27. Referring to stock’s 52-week performance, its high was $1.61, and the low was $0.84. On the whole, LCTX has fluctuated by 33.33% over the past month.
With the market capitalization of Lineage Cell Therapeutics Inc currently standing at about $271.48 million, investors are eagerly awaiting this quarter’s results, scheduled for May 09, 2024 – May 13, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.04, which is expected to increase to -$0.03 for fiscal year -$0.11 and then to about -$0.13 by fiscal year 2025. Data indicates that the EPS growth is expected to be 8.30% in 2025, while the next year’s EPS growth is forecast to be -18.20%.
According to the average forecast, sales growth in current quarter could jump down -32.30%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $17.48 million, representing an increase of 95.40% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that LCTX’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium term indicators have put the stock in the category of 50% Buy while long term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LCTX currently trading nearly 12.19% and 25.52% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.32, while the 7-day volatility ratio is showing 11.47% which for the 30-day chart, stands at 10.94%. Furthermore, Lineage Cell Therapeutics Inc (LCTX)’s beta value is 1.34, and its average true range (ATR) is 0.13.
A comparison of Lineage Cell Therapeutics Inc (LCTX) with its peers suggests the former has fared considerably weaker in the market. LCTX showed an intraday change of 5.88% in last session, and over the past year, it shrunk by -5.26%%.
Data on historical trading for Lineage Cell Therapeutics Inc (AMEX:LCTX) indicates that the trading volumes over the past 10 days have averaged 1.31 million and over the past 3 months, they’ve averaged 905.72K. According to company’s latest data on outstanding shares, there are 188.53 million shares outstanding.
Nearly 0.55% of Lineage Cell Therapeutics Inc’s shares belong to company insiders and institutional investors own 48.04% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 9.98 million shares as on Mar 15, 2024, resulting in a short ratio of 12.7. According to the data, the short interest in Lineage Cell Therapeutics Inc (LCTX) stood at 5.29% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 10.04 million. The stock has risen by 32.11% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LCTX stock heading into the next quarter.
